GURU.Markets stock price, segment price, and overall market index valuation
The company's share price DURECT Corporation
DURECT is a biopharmaceutical company specializing in long-acting treatments. Its stock price is highly volatile, reflecting a long history of clinical successes and failures. The chart exemplifies the high risks and potential rewards of the biotech sector.
Share prices of companies in the market segment - Pharma liver
DURECT Corporation is a biopharmaceutical company developing drugs based on its proprietary drug delivery technologies for the treatment of liver diseases and chronic pain. We have classified it in the "Pharma liver" segment. The chart below shows the overall dynamics of the sector, which is seeking new approaches to treating complex diseases using innovative formulas.
Broad Market Index - GURU.Markets
DURECT Corporation is a biopharmaceutical company developing drugs based on its drug delivery platform for the treatment of liver diseases and other conditions. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
DRRX - Daily change in the company's share price DURECT Corporation
DURECT Corporation's daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about its drug clinical trials, serving as a risk assessment tool.
Daily change in the price of a set of shares in a market segment - Pharma liver
DURECT Corporation is a biotech company. This chart highlights the sector's extreme volatility. Comparison with DRRX, which focuses on liver disease treatments, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
DURECT Corporation is a pharmaceutical company developing drugs for the treatment of liver diseases and other conditions. Its shares, like many in the sector, are extremely volatile and react to news about clinical trials. These movements are part of the overall stock market landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization DURECT Corporation
For DURECT Corporation, annual performance is a reflection of its development pipeline. Its 12-month market capitalization depends on progress in clinical trials of its lead candidate for the treatment of alcoholic hepatitis, as well as revenue from licensing its drug delivery technologies to other pharmaceutical companies.
Annual dynamics of market capitalization of the market segment - Pharma liver
DURECT Corporation is a biopharmaceutical company with a unique drug delivery technology. Its stock performance is entirely dependent on the results of clinical trials and partnerships. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector compared to big pharma.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
DURECT is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization DURECT Corporation
DURECT Corporation is a biopharmaceutical company focused on liver diseases. Its monthly performance is driven by news from its clinical programs. Positive trial data from its lead drug could trigger significant growth, which is typical for biotech.
Monthly dynamics of market capitalization of the market segment - Pharma liver
Biotech companies working in complex areas such as liver disease carry high development risks. The dynamics of their sector, reflected in the chart, serve as a barometer of investor sentiment toward risky R&D projects. A company like DURECT Corporation operates in this environment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
DURECT Corporation, a biopharmaceutical company, has several products at various stages. Its shares are driven by news of clinical trials and partnerships. Their performance is volatile and uncorrelated with the broader market, which is typical for biotech.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization DURECT Corporation
Short-term fluctuations in DURECT, a biopharmaceutical company, reflect news about its developments and products. Sales data for its already approved product, as well as news about the progress of clinical trials for other drugs, create high weekly volatility.
Weekly dynamics of market capitalization of the market segment - Pharma liver
DURECT shares, like the entire biotech sector, are highly dependent on overall investor risk sentiment. Regulatory news and scientific breakthroughs can boost the entire industry. The chart will show how the company stacks up against this high-risk segment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
DURECT shares, like the entire biotech sector, are highly dependent on overall investor risk sentiment. Regulatory news and scientific breakthroughs can boost the entire industry. The chart will show how the company stacks up against this high-risk segment.
Market capitalization of the company, segment and market as a whole
DRRX - Market capitalization of the company DURECT Corporation
The DURECT market capitalization chart is a financial valuation of a biotech company developing drugs based on its drug delivery platform. It reflects investor expectations for its portfolio, particularly its drug for treating alcoholic hepatitis. Its dynamics tell a story about how the market evaluates scientific potential and clinical trial results.
DRRX - Share of the company's market capitalization DURECT Corporation within the market segment - Pharma liver
DURECT Corporation is a biopharmaceutical company developing drugs based on its proprietary drug delivery technology. Its market share reflects both the value of its developments and its track record of clinical successes and failures. The chart below shows how the market values its current portfolio.
Market capitalization of the market segment - Pharma liver
DURECT Corporation is a biopharmaceutical company developing drugs based on its drug delivery platform. The chart below shows the overall market capitalization of the entire sector. Its dynamics are a story of ups and downs. DURECT, like many, has experienced setbacks, but continues its research.
Market capitalization of all companies included in a broad market index - GURU.Markets
Drug development, as seen in the chart, often focuses on niche diseases. DURECT Corporation uses its drug delivery technologies to develop drugs for liver disease and other conditions. Its market cap represents a risky bet on its scientific platform and clinical programs.
Book value capitalization of the company, segment and market as a whole
DRRX - Book value capitalization of the company DURECT Corporation
DURECT's schedule represents the material basis for creating long-acting drugs. Its book value reflects the value of its technology platforms, which enable the encapsulation of active ingredients in biodegradable implants, and its own manufacturing facilities.
DRRX - Share of the company's book capitalization DURECT Corporation within the market segment - Pharma liver
DURECT Corporation, a biopharmaceutical company, has its own R&D and manufacturing capabilities. Its stake in the sector reflects its ownership of laboratories and equipment for developing its drug delivery systems and therapeutic candidates.
Market segment balance sheet capitalization - Pharma liver
DURECT Corporation is a biopharmaceutical company with its own technology platform. Its model is moderately capital-intensive, as it has its own GMP-compliant manufacturing facilities for its drug delivery systems. This demonstrates its commitment to vertical integration within the biotech sector.
Book value of all companies included in the broad market index - GURU.Markets
DURECT's assets are not a large portfolio, but rather a patented drug delivery technology and several promising developments, primarily for the treatment of liver diseases. The company's balance sheet reflects the value of this intellectual property. The chart shows how much capital is invested in this focused biotech company.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - DURECT Corporation
DURECT Corporation is a biopharmaceutical company focused on developing treatments for liver diseases. Its market value is a valuation of its scientific platform and pipeline. The chart shows how investors weigh the potential of its drugs against the risk of clinical failure.
Market to book capitalization ratio in a market segment - Pharma liver
DURECT Corporation is a biopharmaceutical company developing drugs based on its proprietary drug delivery technology. Its valuation is a bet on the success of its platform. This chart shows how the market values the potential of this technology for new drug development compared to its current assets.
Market to book capitalization ratio for the market as a whole
DURECT Corporation is a biopharmaceutical company developing drugs based on its proprietary drug delivery technology. Its market capitalization is based on the potential of this platform. This chart shows how the market values the innovative scientific platform, rather than the company's tangible assets, in anticipation of the commercial success of its products.
Debts of the company, segment and market as a whole
DRRX - Company debts DURECT Corporation
DURECT Corporation is a biopharmaceutical company focused on developing drugs for liver diseases. Advancing candidates through clinical trials is a lengthy and expensive process. Debt financing is an important tool for the company to ensure the continuity of this research.
Market segment debts - Pharma liver
DURECT Corporation is a biopharmaceutical company specializing in developing drugs for liver diseases and other conditions. Its debt policy is an indicator of the maturity of its development pipeline. This chart shows the company's chosen funding path for its clinical programs and how it balances equity and debt capital on its path to commercialization.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio DURECT Corporation
DURECT Corporation, a biopharmaceutical company developing drugs to treat liver diseases, requires significant funding for its research. This chart shows its debt load. Taking on debt to cover R&D costs is common practice, but it carries a significant risk: failure in clinical trials could wipe out the entire investment.
Market segment debt to market segment book capitalization - Pharma liver
DURECT Corporation is a biopharmaceutical company developing drugs based on its drug delivery technology for the treatment of chronic diseases, including liver disease. This chart compares its debt raised for R&D to the total market capitalization of the entire pharmaceutical sector. It reflects its financial strategy for developing innovative treatments.
Debt to book value of all companies in the market
DURECT Corporation is a biopharmaceutical company focused on developing treatments for liver diseases. Its survival and success depend on its ability to fund long-term clinical trials. The chart shows how the company manages its debt. A comparison with the biotech market allows us to assess its financial risks on the path to commercialization.
P/E of the company, segment and market as a whole
P/E - DURECT Corporation
This chart for DURECT Corporation, a biopharmaceutical company, assesses its ability to commercialize its developments. The price-to-earnings ratio, when available, shows how investors view the prospects of its drugs and drug delivery technologies. The dynamics reflect both R&D news and sales success.
P/E of the market segment - Pharma liver
This chart reflects the average valuation for the biopharmaceutical sector—the benchmark for DURECT. Comparison with this metric helps investors understand how the market values the company's development pipeline and drug delivery technology relative to other biotech companies.
P/E of the market as a whole
DURECT Corporation is a biopharmaceutical company developing drugs based on its proprietary drug delivery technology. It focuses on the treatment of liver diseases and other conditions. This chart shows the market's risk appetite. It provides insight into how investors view the potential of DURECT's technology platform and its ability to develop new drugs and form partnerships.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company DURECT Corporation
DURECT Corporation is a biopharmaceutical company developing drugs based on its proprietary drug delivery technology. This chart reflects analyst expectations for its clinical programs. It shows the future profit the market is pricing in based on the belief that its technology will lead to successful commercial products.
%20P%2FE%20DURECT%20Corporation&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-DURECT-Corporation&v=1772632099256 "Chart of the company's future (projected) P/E DURECT Corporation")
Future (projected) P/E of the market segment - Pharma liver
DURECT Corporation is a biopharmaceutical company developing drugs based on its drug delivery technology for the treatment of chronic diseases. This chart shows how its profitability expectations compare to the biotech sector. It reflects how the market views its product portfolio, including its drug for the treatment of alcoholic hepatitis, and the associated clinical risks.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-liver&v=1772632099275 "Future (projected) P/E graph of the market segment - Pharma liver")
Future (projected) P/E of the market as a whole
DURECT Corporation is a biopharmaceutical company developing drugs based on its proprietary drug delivery technology. This chart shows the company's overall risk appetite. DURECT's success depends on progress in clinical trials and partnerships. A positive market environment facilitates these processes, but does not cause them.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772632099304 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit DURECT Corporation
DURECT Corporation is a biopharmaceutical company developing drugs based on its proprietary drug delivery technologies. It focuses on the treatment of acute organ injury and chronic diseases. This graph shows its financial trajectory, which includes both partnership revenue and significant expenditures on its own clinical programs.
Profit of companies in the market segment - Pharma liver
DURECT Corporation is a biopharmaceutical company developing drugs based on its proprietary drug delivery technologies. It focuses on the treatment of acute and chronic conditions, including liver disease. This chart shows the overall financial picture of the pharmaceutical sector, reflecting how innovative drug delivery platforms can create new value.
Overall market profit
DURECT Corporation is a biopharmaceutical company developing drugs based on proprietary drug delivery technologies. Like other companies in the sector, its success depends on the results of clinical trials. The demand for new treatments is independent of the business cycle, but the investment climate in biotech correlates with the overall market situation.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company DURECT Corporation
DURECT Corporation is a biopharmaceutical company developing drugs for the treatment of liver diseases and other serious conditions. Its future depends on the success of clinical trials. The profit forecast is a model in which analysts weigh the potential market size for its drugs against the risks of trial failure.
%20profit%20of%20the%20company%20DURECT%20Corporation&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-DURECT-Corporation&v=1772632099513 "Graph of future (projected) profit of the company DURECT Corporation")
Future (predicted) profit of companies in the market segment - Pharma liver
DURECT Corporation is a biopharmaceutical company using its proprietary drug delivery technology to develop long-acting treatments. This chart shows forecasts for the biotech sector. DURECT's profitability depends on the success of its developments, particularly in the treatment of liver diseases, and on partnerships with major pharmaceutical companies.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-liver&v=1772632099559 "Graph of future (predicted) profits of companies in a market segment - Pharma liver")
Future (predicted) profit of the market as a whole
DURECT Corporation is developing drugs for the treatment of liver diseases. The company's success, currently in clinical trials, depends heavily on its ability to attract investment capital. This chart, showing overall profit expectations, serves as a barometer of market sentiment, which influences the funding of long-term and risky biotech projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772632099603 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - DURECT Corporation
DURECT Corporation is a biopharmaceutical company developing drugs based on its proprietary drug delivery technologies. This chart shows that its valuation is based on future potential. It reflects investors' expectations for the approval and commercialization of its products, rather than current revenue from partnerships.
P/S market segment - Pharma liver
DURECT Corporation is a biopharmaceutical company specializing in the development of drugs for the treatment of liver diseases and other acute conditions. The company uses proprietary drug delivery technologies. This chart reflects the average biotech market valuation, helping to understand how the market views DURECT's scientific platform and clinical development pipeline.
P/S of the market as a whole
DURECT Corporation is a biopharmaceutical company developing drugs based on its proprietary drug delivery system. The company focuses on the treatment of liver diseases. This graph of average market revenue estimates clearly demonstrates that DURECT's valuation is based on the potential of its technology platform, not current sales.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company DURECT Corporation
DURECT Corporation is a biopharmaceutical company using its technologies to develop extended-release drugs. This chart shows how investors assess the future potential of its developments, particularly for the treatment of liver diseases. The assessment is based on expectations of successful clinical trials and future commercial revenue.
%20P%2FS%20DURECT%20Corporation&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-DURECT-Corporation&v=1772632099715 "The graph of the company's future (projected) P/S DURECT Corporation")
Future (projected) P/S of the market segment - Pharma liver
DURECT Corporation is a biopharmaceutical company developing drugs based on its proprietary drug delivery technology. This chart compares the company's future revenue expectations with its industry. It reflects the market's assessment of both its own clinical programs and the licensing potential of its technologies.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20liver&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-liver&v=1772632099732 "Future (projected) P/S market segment graph - Pharma liver")
Future (projected) P/S of the market as a whole
DURECT Corporation is a biopharmaceutical company developing drugs based on its proprietary drug delivery technology. This schedule reflects confidence in future growth, as DURECT works to improve existing treatments. The success of its platform could improve drug efficacy and safety, creating new value in the pharmaceutical industry.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772632099742 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales DURECT Corporation
DURECT Corporation is a biopharmaceutical company developing drugs based on its drug delivery technology. Its revenue, shown in this chart, is generated through royalties and license fees from partners who incorporate its technology into their products, as well as from collaboration agreements.
Sales of companies in the market segment - Pharma liver
DURECT Corporation is a biopharmaceutical company specializing in the development of drugs for the treatment of liver diseases and acute pain. They utilize proprietary drug delivery technologies. This chart illustrates the state of the pharmaceutical market, where innovative platforms like DURECT's can improve the efficacy and safety of therapy.
Overall market sales
DURECT Corporation is a biopharmaceutical company developing drugs based on proprietary drug delivery technologies. Its success depends on progress in clinical trials. The growth in total economic revenue, reflected in this chart, improves the investment climate, facilitating capital raising to fund long-term, capital-intensive research and development.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company DURECT Corporation
DURECT Corporation is a biopharmaceutical company developing drugs based on its proprietary drug delivery technology. One of its key products is aimed at treating alcoholic hepatitis. This graph reflects analysts' expectations for the success of clinical trials and potential regulatory approval of its drugs.
%20sales%20of%20the%20company%20DURECT%20Corporation&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-DURECT-Corporation&v=1772632099835 "Schedule of future (projected) sales of the company DURECT Corporation")
Future (projected) sales of companies in the market segment - Pharma liver
DURECT Corporation is a biopharmaceutical company developing drugs based on its proprietary drug delivery technology for the treatment of chronic diseases, particularly liver disease. This chart shows forecasts for the pharmaceutical sector, providing context for assessing how innovative treatment approaches could impact the entire industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-liver&v=1772632099935 "Schedule of future (projected) sales of companies in the market segment - Pharma liver")
Future (projected) sales of the market as a whole
DURECT Corporation, a biopharmaceutical company developing long-acting treatments, sees this chart as an indicator of investment activity in the sector. The strong economic environment reflected here facilitates the influx of capital needed to complete clinical trials and bring innovative therapeutic solutions to market.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772632099957 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality DURECT Corporation
DURECT Corporation is a biopharmaceutical company developing drugs based on its proprietary delivery technologies. This chart reflects its financial position. It shows whether the company is investing in clinical trials or is already generating revenue from commercialized products and partnerships.
Market segment marginality - Pharma liver
DURECT Corporation is a biopharmaceutical company specializing in the development of drugs for liver and other chronic diseases. Operational efficiency in this field is determined by the efficient allocation of resources across various research programs. This chart allows you to assess how well-aligned the company's strategy is compared to its competitors.
Market marginality as a whole
DURECT Corporation is a biopharmaceutical company developing drugs based on its proprietary drug delivery technology. This chart shows average profitability, and DURECT uses its platform to create products with improved properties. Their profitability depends on the success of their developments and licensing agreements.
Employees in the company, segment and market as a whole
Number of employees in the company DURECT Corporation
DURECT Corporation is a biopharmaceutical company developing drugs based on its proprietary delivery technology. This chart shows the size of its team of scientists and clinicians. The staffing dynamics reflect research and development activity, as well as the progress of its therapeutic programs.
Share of the company's employees DURECT Corporation within the market segment - Pharma liver
DURECT Corporation is a biopharmaceutical company specializing in the development of drugs for liver diseases and acute pain. This chart shows the percentage of all scientists and clinicians in this complex therapeutic area that DURECT attracts. This reflects its scientific focus and decades of experience in creating innovative drug delivery systems.
Number of employees in the market segment - Pharma liver
DURECT Corporation is a biopharmaceutical company developing drugs based on its drug delivery technology. Its staff consists of scientists and clinical development specialists. This chart shows its research activity. The dynamics of its staff reflect the phases of product development, from early research to late-stage clinical trials.
Number of employees in the market as a whole
DURECT Corporation is a biopharmaceutical company developing treatments for liver diseases. Its market capitalization and ability to hire top talent depend on its research results. This chart shows the overall picture, but in the world of biotech, a single successful drug can create hundreds of jobs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company DURECT Corporation (DRRX)
DURECT is a biopharmaceutical company developing drugs with a unique delivery system. This chart shows that the market highly values its technology platform. The high market capitalization per employee suggests that the company's value lies in its intellectual property.
%20of%20the%20company%20DURECT%20Corporation%20(DRRX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-DURECT-Corporation-DRRX&v=1772632100366 "Chart of market capitalization per employee (in thousands of dollars) of the company DURECT Corporation (DRRX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma liver
DURECT Corporation is a biopharmaceutical company developing drugs for the treatment of liver diseases and other conditions. Its value is determined by its pipeline of developments at various stages. This chart shows the investors' bet on the company's scientific team and its ability to bring drugs to market, measured per employee.
%20by%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-liver&v=1772632100415 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma liver")
Market capitalization per employee (in thousands of dollars) for the overall market
DURECT Corporation is a biopharmaceutical company developing drugs based on proprietary drug delivery systems. It focuses on the treatment of liver diseases and acute pain. This chart illustrates how the market values a company whose technology platform can improve existing drugs and create new ones, creating a high potential value per employee.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772632100451 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company DURECT Corporation (DRRX)
DURECT Corporation is a biopharmaceutical company developing drugs to treat liver diseases (such as alcoholic hepatitis). It's an R&D company. This graph, being negative, shows the investment phase. It reflects how much capital the company is investing in each of its scientists to advance this complex therapy.
%20Chart%20DURECT%20Corporation%20(DRRX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-DURECT-Corporation-DRRX&v=1772632100453 "Company Profit Per Employee (in thousands of dollars) Chart DURECT Corporation (DRRX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma liver
DURECT (DRRX) is a biopharmaceutical company specializing in developing treatments for liver diseases (such as alcoholic hepatitis). Being in the clinical stage, the company has unstable revenues. This chart reflects R&D efficiency. It shows how efficiently the research team uses capital to advance its candidates through expensive trials.
%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-liver&v=1772632100550 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma liver")
Profit per employee (in thousands of dollars) for the market as a whole
DURECT Corporation is a biopharmaceutical company developing treatments for liver diseases and other conditions. The company has both proprietary R&D and licensed drug delivery technologies. This chart reflects a hybrid model. Earnings per employee can fluctuate: losses from in-house R&D can be offset by profits from licensing fees.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772632100582 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee DURECT Corporation (DRRX)
DURECT Corporation is a biopharmaceutical company developing drugs based on its proprietary delivery technology. This chart illustrates their business model. Revenue per employee can come from licensing agreements with other pharmaceutical companies as well as from future sales of their own drugs, if approved.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-DURECT-Corporation-DRRX&v=1772632100696 "Sales chart per company employee DURECT Corporation (DRRX)")
Sales per employee in the market segment - Pharma liver
DURECT Corporation is a biopharmaceutical company developing drugs based on its drug delivery platform, focusing on liver diseases. This chart shows the average revenue per employee in the sector. It serves as a benchmark to help investors evaluate the commercial potential and future productivity of DURECT's R&D platform compared to other biotech companies.
Sales per employee for the market as a whole
DURECT Corporation (DRRX) is a biopharmaceutical company developing drugs for the treatment of liver disease (MASH) and other conditions. They also have drug delivery technology. This chart shows current revenue (primarily from partnerships using their technology) per employee while their core drugs are in R&D.
Short shares by company, segment and market as a whole
Shares shorted by company DURECT Corporation (DRRX)
DURECT Corporation is a biopharmaceutical company developing drugs based on its drug delivery platform. Its focus is on liver diseases. The chart shows the number of investors who have given up on the company after years of development without any approved products. They are betting that its current liver treatment trials will also fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-DURECT-Corporation-DRRX&v=1772632100924 "Short Shares Chart for the Company DURECT Corporation (DRRX)")
Shares shorted by market segment - Pharma liver
DURECT Corporation focuses on treating liver diseases such as alcoholic hepatitis. This chart demonstrates the skepticism surrounding this entire niche. Its growth suggests that investors are massively betting against the entire liver drug development field (including NASH), which is known as a "graveyard" of clinical trials.
Shares shorted by the overall market
DURECT Corporation is a biotech company focused on liver diseases. The company has a history of R&D failures. This chart illustrates the overall market pessimism. When fear mounts, investors are merciless to companies with a "bad" history. They don't give second chances and sell off shares, fearing they'll run out of money before success.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator DURECT Corporation (DRRX)
This oscillator for DURECT reflects the company's diversified biotech portfolio. The company has both proprietary developments (for example, for treating liver disease) and technologies for sustained drug delivery. An "overbought" reading (above 70) could be caused by positive data on one of its key drugs. A failed trial or a below-expected selloff would lead to an "oversold" reading (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-DURECT-Corporation-DRRX&v=1772632101130 "RSI 14 indicator chart for the company's stock DURECT Corporation (DRRX)")
RSI 14 Market Segment - Pharma liver
DURECT (DRRX) is a biotech drug delivery company. Their specialty is *long-term* (SABER) *delivery* technologies (depot injections) for the treatment of *pain* and *liver disease*. The "Pharma liver" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of the *entire* segment. It's vital to understand: is DRRX's growth due to their R&D or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
DURECT (DRRX) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast DRRX (DURECT Corporation)
DURECT (DRRX) is a biopharmaceutical company developing long-acting therapies, including those for liver disease (MASH). This chart shows the average target price. It reflects analysts' speculative valuation of this technology and clinical trial data in the complex field of hepatology.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-DRRX-DURECT-Corporation&v=1772632101275 "A chart showing analyst consensus forecasts for the expected stock price. DRRX (DURECT Corporation)")
The difference between the consensus estimate and the actual stock price DRRX (DURECT Corporation)
DURECT (DRRX) is a biopharmaceutical company whose main asset (Larsucosterol) is being developed to treat severe alcoholic hepatitis. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high, yet speculative, potential analysts see in their lead drug candidate.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-DRRX-DURECT-Corporation&v=1772632101283 "A chart showing the difference between the consensus forecast and the actual stock price. DRRX (DURECT Corporation)")
Analyst consensus forecast for stock prices by market segment - Pharma liver
DURECT Corporation is a biopharmaceutical company developing drugs for the treatment of liver disease (NASH) and acute pain using its drug delivery platform. This chart shows analysts' overall expectations for the liver pharma sector. It reflects whether experts believe a breakthrough in fatty liver treatment is possible.
Analysts' consensus forecast for the overall market share price
DURECT is a clinical-stage biotech company working on liver diseases and acute organ injury. It's a risky R&D venture. This chart, which measures the market's overall risk appetite, is crucial. When optimism prevails, investors are willing to fund capital-intensive R&D projects. When pessimism rises, funding for companies like DRRX becomes scarce.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index DURECT Corporation
DURECT Corp. is a biotech company with a hybrid model. They have an R&D pipeline (focused on liver diseases, such as NES) and a technology platform (drug delivery), which they license to partners (Posimir). This chart is a summary indicator of their R&D strategy. It reflects their progress in clinical trials and their ability to generate licensing revenue.
AKIMA Market Segment Index - Pharma liver
DURECT Corporation (DRRX) is a biopharmaceutical company developing drugs based on its proprietary drug delivery technology. Their key product, Posurvepitide, targets liver diseases. The chart shows the segment average. It helps investors assess how the risks and potential of DURECT's developments in the complex field of hepatology compare to the average.
The AKIM Index for the overall market
DURECT is a biopharmaceutical company developing epigenetic therapies for the treatment of acute organ failure (alcoholic hepatitis). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative scientific story compares to overall economic trends and trial data.
